Cargando…
Comparative Effectiveness of Ustekinumab Versus Adalimumab in Induction of Clinical Response and Remission in Crohn’s Disease: Experience of a Real-World Cohort at a Tertiary Care Inflammatory Bowel Disease Referral Center
BACKGROUND: There is paucity of head-to-head studies comparing the effectiveness of ustekinumab (UST) and adalimumab (ADA) in Crohn’s disease (CD). Here we provide a real-world comparison of these two agents. METHODS: We conducted an ambidirectional cohort study. Each patient included had moderate t...
Autores principales: | Ahmed, Zunirah, Venkata, Krishna, Zhang, Nan, Malik, Talha A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785289/ https://www.ncbi.nlm.nih.gov/pubmed/31636774 http://dx.doi.org/10.14740/gr1194 |
Ejemplares similares
-
Comparison of Effectiveness and Safety of Ustekinumab and Adalimumab As Induction or Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: A Systematic Review and Meta-Analysis
por: Chenna, Venkata Sai Harshabhargav, et al.
Publicado: (2023) -
Adalimumab for induction of remission in patients with Crohn's disease: a systematic review and meta-analysis
por: Yin, Juntao, et al.
Publicado: (2022) -
Ustekinumab in Crohn's disease: Real‐world outcomes from the Sicilian network for inflammatory bowel diseases
por: Viola, Anna, et al.
Publicado: (2021) -
Budesonide Use and Hospitalization Rate in Crohn’s Disease: Results From a Cohort at a Tertiary Care IBD Referral Center
por: Orr, Jordan, et al.
Publicado: (2016) -
Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease
por: Wu, Kai-Chun, et al.
Publicado: (2016)